Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction

Drugs under Experimental and Clinical Research

Volumn 30, Issue 2, 2004, Pages 55-65

  Papadopoulos, Dimitris P ^a   Economou, E V ^b   Makris, T K ^a   Kapetanios, K J ^b   Moyssakis, I ^a   Votteas, V E ^a   Toutouzas, P K ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; PERINDOPRIL; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION SIZE; HEART VENTRICLE REMODELING; HEART VENTRICULOGRAPHY; HOSPITAL ADMISSION; HUMAN; MALE; PROTEIN DETERMINATION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; MYOCARDIAL INFARCTION; PROTEASE INHIBITORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 3142723115     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cleutjens J.P. The role of matrix metalloproteinases in heart disease. Cardiovasc. Res., 32, 816, 1996.
2. Dollery C.M., McEwan J.R., Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ. Res., 77, 863, 1995.
3. Takahashi S., Berry A.C., Factor S.M. Collagen degradation in ischemic rat hearts. Biochem. J., 265, 233, 1990.
4. Caulfield J.B., Workowicz P. Inducible collagenolytic activity in isolated perfused rat hearts. Am. J. Pathol., 131, 199, 1988.
5. Cleutjens J.P., Kandala C.J., Weber K.T. Regulation of collagen degradation in the rat myocardium after infarction. J. Mol. Cell Cardiol., 27, 1281, 1995.
6. Tyagi S.C., Campbell S.E., Reddy H.K., et al. Matrix metalloproteinase activity expression in infarcted non-infracted and dilated cardiomyopathic human hearts. Mol. Cell Biochem., 155, 13, 1996.
7. Pfeffer M.A., Braunwald E., Moye L.A., et al. on behalf of the SAVE Investigators. Effects of captopril on mortality and morbidity in patients with dysfunction after MI: Results of the survival and ventricular enlargement. N. Engl. J. Med., 327, 669, 1992.
8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet, 342, 821, 1993.
9. Weber K.T. Targeting pathological remodeling concepts of cardio protection and reparation. Circulation, 102, 1342, 2000.
10. ACE Inhibitor Myocardial Infarction Collaborative Group. Indication for ACE inhibitors in the early treatment of acute myocardial infarction systematic overview of individual data from 100,000 patients in randomized trials. Circulation, 97, 2202, 1998.
11. Pfeffer M.A. ACE inhibitors in acute myocardial infarction. Patient selection and timing. Circulation, 97, 2192, 1998.
12. Khalil M.E., Basher A.W., Brown E.J., et al. A remarkable medical story: Benefits of angiotensin converting enzyme inhibitors in cardiac patients. J. Am. Coll. Cardiol., 37, 1757, 2001.
13. Lindpaintner K., Lu W., Neidermajer N., et al. Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. J. Mol. Cell Cardiol., 25, 133, 1993.
14. Sadoshima J., Jahn L., Takashashi T., et al. Molecular characterization of the stretch-induced adaptation of cultured cardiac cell. An in vitro model of load-induced cardiac hypertrophy. J. Biol. Chem., 627, 10552, 1992.
15. McLennan S.V., Kelly D.J., Cox A.J., et al. Decreased matrix degradation in diabetic nephropathy: Effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia, 45, 268, 2002.
16. Greene D.G., Carlisle R., Grant C., et al. Estimation of left ventricular volume by one-plane cineangiography. Circulation, 35, 61, 1967.
17. Bell R.M., Smith C.H., Reeder S.G. Cardiac catheterization and angiography. In: Ciuliami E.R., Gerth B.J., McGoon M.D., Hayes D.L., Schaff H.V. (Eds.). "Mayo Clinic Practice of Cardiology." Third Edition. Mosby St. Louis, Baltimore-Boston, 1966, p. 357.
18. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J. Am. Soc. Echocardiogr., 2(5), 358, 1989.
19. Feigenbaum H., Popp R.L., Wolfe S.B., et al. Ultrasound measurements of the left ventricle. A correlative study with angiography. Arch. Intern. Med., 129, 461, 1972.
20. Zhang T., Fujimoto N., Iwata H., et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinases-1 (interstitial collagenase) using monoclonal antibodies. Clin. Chim. Acta. 219, 1, 1993.
21. Clark I.M., Powell L.K., Wright J.K., et al. "Matrix 1991." Cambridge, UK 1990, pp. 76-85.
22. Cooksley S., Hipkiss J.B., Tickle S.P., et al. "Matrix 1990." Celltech Ltd., UK 1990, pp. 285-291.
23. Pfeffer J.M., Pfeffer M.A., Fletcher P.J., et al. Progressive ventricular remodeling in rat with myocardial infarction. Am. J. Physiol., 260, H1406, 1991.
24. Rumberger J.A. Ventricular dilatation and remodeling after myocardial infarction. Mayo Clin. Proc., 69, 664, 1994.
25. Wiek H., Van Glist J., Herre K., et al. on behalf of the CATS investigators. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? J. Am. Coll. Cardiol., 28, 114, 1996.
26. Fourth International Study of Infarct Survival Collaborative Group. Fourth International study of infarct survival: A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet, 345, 669, 1995.
27. Rohde L.E., Durcharme A., Arroyo L.H., et al. Matrix metalloproteinases inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation, 99, 3063, 1999.
28. Anversa P., Olivetti G., Capasso J.M. Cellular basis of ventricular remodeling after myocardial infarction. Am. J. Cardiol., 68, 7, 1991.
29. Olivetti G., Capasso J.M., Sonnenbleck E.H., et al. Side-to-side slippage of myocytes wall remodeling acutely after myocardial infarction in rats. Circ. Res., 67, 23, 1990.
30. Irwin M.W., Mak S., Mann D.L., et al. Tissue expression and immunolocalization of tumor necrosis factor-α in post infarction dysfunctional myocardium. Circulation, 99, 1492, 1999.
31. Brenner D.A., O'Hara M., Angel P., et al. Prolonged activation of jun and collagenase genes by tumor necrosis factor-α Nature, 337, 661, 1989.
32. Bozkurt B., Kribbs S., Clubb F. Jr., et al. Pathophysiology relevant concentration of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation, 97, 1392, 1998.
33. Sivasubramanian N., Coker M.L., Kurrelmeyer K.M., et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation, 104, 826, 2001.